Active substance
Results for the substance emtricitabine tenofovir alafenamide
4 results
About this active substance
The combination of emtricitabine and tenofovir alafenamide is used for the treatment of HIV infection and for pre-exposure prophylaxis (PrEP). It works by inhibiting reverse transcriptase, preventing HIV replication.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, headaches, fatigue, and increased cholesterol levels.
This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal and hepatic function.
This medication is a modern option for managing HIV infection, offering an improved safety profile compared to other therapeutic regimens.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, headaches, fatigue, and increased cholesterol levels.
This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal and hepatic function.
This medication is a modern option for managing HIV infection, offering an improved safety profile compared to other therapeutic regimens.